z-logo
open-access-imgOpen Access
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
Author(s) -
Gerald M. Higa,
Corbin Sypult
Publication year - 2016
Publication title -
clinical medicine insights oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 26
ISSN - 1179-5549
DOI - 10.4137/cmo.s32810
Subject(s) - mechanism (biology) , neurotoxicity , cancer , function (biology) , bioinformatics , microtubule , computational biology , medicine , biology , neuroscience , pharmacology , toxicity , genetics , philosophy , epistemology
Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our under-standing of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom